At IMBCR, we have boldly set out to reimagine how we approach treatment, management, and drug development strategies for multiple myeloma and other devastating malignancies.
We focus on the individual needs of patients, not just treatment, but all-encompassing care. Working alongside industry leaders and other centers of excellence from around the world, we explore available drugs and novel agents to determine optimal and personalized combinations to maximize their benefits. Our mission is to advance the treatment of myeloma by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care.
Patients with multiple myeloma want to know their physician is giving them the best care possible.
Focused on Today
IMBCR research enables clinicians to identify the disease faster, optimize treatment plans, and provide most effective therapy available. See how IMBCR initiatives are addressing this.
Quality of Life
Living your Best Life!
We need your support to make this possible.
Our aim is to provide clinicians “decision assistance” for patients with relapsed &/or refractory myeloma, allowing them to deliver optimal data-driven treatment.
Dreaming of Living Life Free of Myeloma
Ultimately our goal is to eradicate myeloma and allow patients to continue to live their best life!
IMBCR future initiative
You Can Help
Multiple myeloma is a rare blood cancer of malignant cells found in the bone marrow that has had many therapeutic breakthroughs in the past decade; and, as a result, has become perhaps the most complicated cancer to treat and manage.
The Institute for Myeloma & Bone Cancer Research (IMBCR), formed in 2003, is dedicated to advance the treatment of myeloma by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care.
It is through the support of our donors that IMBCR is able to reimagine drug development strategies for multiple myeloma & determine optimal and personalized combinations to maximize their benefits for patients.
We are dedicated to ALL patients living their best life.
Become a fundraising leader of IMBCR today.
Dr. James R. Berenson, a global innovative thought leader in multiple myeloma, formed the Institute for Myeloma & Bone Cancer Research (IMBCR) in 2003. This offers scientists the opportunity to work in an unencumbered environment to explore new directions in a state of the art, self-contained laboratory facility. Dr. Berenson leads a team of dedicated scientists with extensive expertise in cancer research, particularly in the fields of myeloma, metastatic bone cancer, genetics, immunology, tumor microenvironment. They use models of myeloma and other bone cancers to make groundbreaking discoveries that have led to many new treatments for these diseases.